Untapped Fertility Market Microgenesis operates in the fertility and microbiome space with a unique functional microbiome test, presenting an opportunity to upsell to fertility clinics, OB/GYN practices, and reproductive endocrinology centers seeking novel diagnostic tools and personalized treatment approaches.

Early Stage Validation With recent alpha tests, a $1.6M raise, and partnerships formed after IndieBio, there is credibility to approach early adoption clinics and investor-backed healthcare networks that value validated pilots and evidence-based outcomes.

Strategic Partnerships Existing ties with Renegade Bio and IndieBio indicate a pattern of collaboration; leverage these channels to access broader US market networks, accelerator alumni, and potential co-development or distribution agreements.

Digital and Outreach Channels A tech stack including Google Ads, Hotjar, AWS, and WhatsApp Business suggests readiness for scalable marketing and customer support; target digital health platforms, patient education hubs, and fertility communities for patient acquisition partnerships.

Financial Levers Current revenue tier and $2.3M funding imply budget for pilot programs, clinician training, and reimbursement discussions; pursue value-based partnerships with clinics and payers to demonstrate cost-effective improvements in fertility outcomes.